John C Alexander
Medical Practice in Princeton, NJ
License number
New Jersey 25MA02707300
Issued Date
Apr 4, 1973
Expiration Date
Jun 30, 2007
Category
Medical Examiners
Type
Medical Doctor
Address
Address
Princeton, NJ
Personal information
See more information about John C Alexander at radaris.comName
Address
Phone
473 Monmouth Ave, Brick, NJ 08723
Professional information
Combination Therapy Of Angiotensin Converting Enzyme Inhibitor And Aldosterone Antagonist For Reducing Morbidity And Mortality From Cardiovascular Disease
US Patent:
6410524, Jun 25, 2002
Filed:
Nov 5, 1999
Appl. No.:
09/434685
Inventors:
Alfonzo T. Perez - Lake Forest IL
Debra J. Asner - Morton Grove IL
Richard J. LaChapelle - Wilmette IL
John C. Alexander - Princeton NJ
Barbara Roniker - Chicago IL
Debra J. Asner - Morton Grove IL
Richard J. LaChapelle - Wilmette IL
John C. Alexander - Princeton NJ
Barbara Roniker - Chicago IL
Assignee:
G. D. Searle Co. - Chicago IL
International Classification:
A61K 31585
US Classification:
514175
Abstract:
Combinations of an ACE inhibitor, an aldosterone antagonist, and a loop diuretic are described for use in treatment of circulatory disorders. Of particular interest are therapies using captopril, enalapril or lisinopril co-administered with spironolactone. This co-therapy would be particularly useful to reduce the death rate or the number of non-fatal hospitalizations or prevent the progression of congestive heart failure in patients with cardiovascular disease.
Methods Of Treating Heart Failure And Hypertension Using Combinations Of Eplerenone And An Angiotensin Converting Enzyme Inhibitor
US Patent:
6747020, Jun 8, 2004
Filed:
Feb 15, 2002
Appl. No.:
10/077134
Inventors:
Alfonzo T. Perez - Lake Forest IL
Debra J. Asner - Morton Grove IL
Richard J. LaChapelle - Wilmette IL
John C. Alexander - Princeton NJ
Barbara Roniker - Chicago IL
Debra J. Asner - Morton Grove IL
Richard J. LaChapelle - Wilmette IL
John C. Alexander - Princeton NJ
Barbara Roniker - Chicago IL
Assignee:
Pharmacia Corporation - St. Louis MO
International Classification:
A61R 31585
US Classification:
514175
Abstract:
Methods of using eplerenone, an angiotensin converting enzyme inhibitor and optionally a diuretic are described for treatment of heart failure and hypertension.
Combination Therapy Of Angiotensin Converting Enzyme Inhibitor And Aldosterone Antagonist For Reducing Morbidity And Mortality From Cardiovascular Disease
US Patent:
2004016, Aug 26, 2004
Filed:
Jan 8, 2004
Appl. No.:
10/753610
Inventors:
Alfonzo Perez - Lake Forest IL, US
Debra Asner - Morton Grove IL, US
Richard LaChapelle - Wilmette IL, US
John Alexander - Princeton NJ, US
Barbara Roniker - Chicago IL, US
Debra Asner - Morton Grove IL, US
Richard LaChapelle - Wilmette IL, US
John Alexander - Princeton NJ, US
Barbara Roniker - Chicago IL, US
Assignee:
G.D. Searle & Co. - Chicago IL
International Classification:
A61K031/58, A61K031/549, A61K031/401
US Classification:
514/171000, 514/223500, 514/423000
Abstract:
Combinations of an ACE inhibitor, an aldosterone antagonist, and a loop diuretic are described for use in treatment of circulatory disorders. Of particular interest are therapies using captopril, enalapril or lisinopril co-administered with spironolactone. This co-therapy would be particularly useful to reduce the death rate or the number of non-fatal hospitalizations or prevent the progression of congestive heart failure in patients with cardiovascular disease.
Triple Therapy Of Angiotensin Converting Enzyme Inhibitor Epoxy-Steroidal Aldosterone Antagonist And Diuretic Or Digoxin For Treatment Of Cardiovascular Disease
US Patent:
2004007, Apr 22, 2004
Filed:
May 19, 2003
Appl. No.:
10/440691
Inventors:
John Alexander - Princeton NJ, US
Barbara Roniker - Chicago IL, US
Subhash Desai - Wilmette IL, US
Barbara Roniker - Chicago IL, US
Subhash Desai - Wilmette IL, US
Assignee:
G.D. Searle & Co. - Chicago IL
International Classification:
A61K031/58, A61K031/401
US Classification:
514/171000, 514/423000
Abstract:
Combinations of an ACE inhibitor and an epoxy-steroidal aldosterone receptor antagonist are described for use in treatment of circulatory disorders. Of particular interest are therapies using epoxy-steroidal-type aldosterone receptor antagonist compounds, such as eplerenone, in combination with an angiotensin converting enzyme inhibitor. This co-therapy would be particularly useful to treat congestive heart failure while avoiding or reducing aldosterone-antagonist-induced side effects such as hyperkalemia.
Epoxy-Steroidal Aldosterone Antagonist And Beta-Adrenergic Antagonist Combination Therapy For Treatment Of Congestive Heart Failure
US Patent:
2005021, Sep 29, 2005
Filed:
Jun 2, 2005
Appl. No.:
11/143310
Inventors:
John Alexander - Princeton NJ, US
Joseph Schuh - St. Louis MO, US
Joseph Schuh - St. Louis MO, US
International Classification:
A61K031/58
US Classification:
514171000, 514172000
Abstract:
A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of a beta-adrenergic antagonist is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred beta-adrenergic antagonists are those compounds having high potency and bioavailability. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compounds characterized by the presence of a 9α,11α-substituted epoxy moiety. A preferred combination therapy includes the beta-adrenergic antagonist metoprolol ((±)1-(isopropylamino)-3-[p-(2-methoxyethyl)phenoxyl]-2-propanolol succinate) and the aldosterone receptor antagonist epoxymexrenone.
Epoxy Steroidal Aldosterone Antagonist And Beta-Adremergic Antagonist Combination Therepy For Treatment Of Congestive Heart Failure
US Patent:
2004023, Nov 25, 2004
Filed:
Jun 7, 2004
Appl. No.:
10/343166
Inventors:
John Alexander - Princeton NJ, US
Joseph Schuh - St Louis MO, US
Joseph Schuh - St Louis MO, US
International Classification:
A61K031/58
US Classification:
514/173000, 514/174000
Abstract:
A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of a beta-adrenergic antagonist is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred beta-adrenergic antagonists are those compounds having high potency and bioavailability. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compounds characterized by the presence of a 9, 11-substituted epoxy moiety. A preferred combination therapy includes the beta-adrenergic antagonist metoprolol ((±)1-(isopropylamino)-3-[p-(2-methoxyethyl)phenoxyl]-2-propanolol succinate) and the aldosterone receptor antagonist epoxymexrenone.
Epoxy Steroidal Aldosterone Antagonist And Beta-Adrenergic Antagonist Combination Therapy For Treatment Of Congestive Heart Failure
US Patent:
2002012, Sep 5, 2002
Filed:
Jul 27, 2001
Appl. No.:
09/917403
Inventors:
John Alexander - Princeton NJ, US
Joseph Schuh - St. Louis MO, US
Joseph Schuh - St. Louis MO, US
International Classification:
A61K031/58, A61K031/405, A61K031/137
US Classification:
514/173000, 514/171000, 514/651000, 514/415000
Abstract:
A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of a beta-adrenergic antagonist is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred beta-adrenergic antagonists are those compounds having high potency and bioavailability. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compounds characterized by the presence of a 9,11-substituted epoxy moiety. A preferred combination therapy includes the beta-adrenergic antagonist metoprolol ((±)1-(isopropylamino)-3-[p-(2-methoxyethyl)phenoxyl]-2-propanolol succinate) and the aldosterone receptor antagonist epoxymexrenone.
Combination Therapy Of Angiotensin Converting Enzyme Inhibitor And Eplerenone For Treatment Of Cardiovascular Disease
US Patent:
2005025, Nov 10, 2005
Filed:
Aug 6, 2003
Appl. No.:
10/637070
Inventors:
John Alexander - Princeton NJ, US
Barbara Roniker - Chicago IL, US
Subhash Desai - Wilmette IL, US
Barbara Roniker - Chicago IL, US
Subhash Desai - Wilmette IL, US
Assignee:
G. D. Searle & Co. - Chicago IL
International Classification:
A61K031/56, A61K031/401
US Classification:
514171000, 514423000
Abstract:
Combinations of an ACE inhibitor and an epoxy-steroidal aldosterone receptor antagonist are described for use in treatment of circulatory disorders. Of particular interest are therapies using epoxy-steroidal-type aldosterone receptor antagonist compounds, such as eplerenone, in combination with an angiotensin converting enzyme inhibitor. This co-therapy would be particularly useful to treat congestive heart failure while avoiding or reducing aldosterone-antagonist-induced side effects such as hyperkalemia.